A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor

NCT03219554 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Thymic Cancer

Interventions

DRUG: Palbociclib

Sponsor

Samsung Medical Center